following a full submission:
glecaprevir-pibrentasvir (Maviret®) is accepted for use within NHS Scotland.
Indication under review: Treatment of chronic hepatitis C virus (HCV) infection in adults.
Glecaprevir-pibrentasvir is associated with high rates of sustained virologic suppression in patients with all genotypes of chronic HCV infection. In treatment-naïve non-cirrhotic patients with genotype 3 infection it was non-inferior to a direct acting anti-viral regimen that included a non-structural protein 5B (NS5B) inhibitor plus NS5A inhibitor.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of glecaprevir-pibrentasvir. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.
Download detailed advice380KB (PDF)
- Medicine name:
- glecaprevir/pibrentasvir (Maviret)
- SMC ID:
- Treatment of chronic hepatitis C virus (HCV) infection in adults.
- Pharmaceutical company
- AbbVie Ltd
- BNF chapter
- Submission type
- Date advice published
- 13 November 2017